CNS High Grade Glioma

Abstract

Since the publication of the 2016 edition of the WHO Classification of CNS Tumors, advances in neuropathology have enhanced our understanding of the molecular underpinnings of CNS tumors, providing new elements to refine their classification and improve pathological diagnosis of these neoplasms. This chapter will review the highlights of the updated recommendations which provide guidance for how even in the absence of histopathological characteristics of the highest malignancy grade, molecular markers can be used to reach a diagnosis of glioblastoma, IDH–wild-type or astrocytoma, IDH-mutant, grade IV. These changes have important implications for the management of patients with CNS tumors in current neuro-oncology practice.